SEC Form S-8 filed by LMF Acquisition Opportunities Inc.
$LMAO
Consumer Electronics/Appliances
Industrials
As filed with the Securities and Exchange Commission on February 9, 2024
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OF 1933
SeaStar Medical Holding Corporation
(Exact name of registrant as specified in its charter)
|
Delaware
|
|
001-39927
|
|
(State or other jurisdiction of
incorporation or organization) |
|
(I.R.S. Employer
Identification No.) |
|
80216
|
||
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
SeaStar Medical Holding Corporation 2022 Omnibus Incentive Plan
(Full title of the plan)
Eric Schlorff
Chief Executive Officer
3513 Brighton Blvd.
Chief Executive Officer
3513 Brighton Blvd.
Suite 410
Denver, CO 80216
(Name and address of agent for service)
(Telephone number, including area code, of agent for service)
With copies of all notices, orders, and communications to:
|
Albert Lung, Esq.
Morgan, Lewis & Bockius LLP
1400 Page Mill Road
Palo Alto, California 94304
(650) 843-4000
|
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging
growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer
|
|
☐
|
|
Accelerated filer
|
|
☐
|
|
Non-accelerated filer
|
|
☒
|
|
Smaller reporting company
|
|
☒
|
|
|
|
Emerging growth company
|
|
☒
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
This Registration Statement on Form S-8 (the “Registration Statement”), relating to the SeaStar Medical Holding Corporation 2022 Omnibus Incentive Plan (the “Incentive
Plan”), is being filed pursuant to General Instruction E to Form S-8, for the purpose of registering an aggregate of 1,180,000 shares (the “Shares”) of the common stock, par value $0.0001 per share (the “Common Stock”), of SeaStar Medical Holding
Corporation (the “Company” or the “Registrant”), reserved for issuance under the Incentive Plan. The Shares are securities of the same class and relate to the same employee benefit plan for which Registration Statement on Form S-8 has previously been
filed and is effective. Accordingly, this Registration Statement incorporates by reference the content of the Registration Statement on Form S-8, File No. 333-270070, filed with the Securities and Exchange
Commission (the “SEC”) on February 27, 2023 by the Company, relating to the Incentive Plan, and the information required by Part II is omitted, except as supplemented by the information set forth below.
PART II.
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The following documents filed by the Registrant with the SEC pursuant to the Securities Act of 1933, as amended (the “Securities Act”), and the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), are hereby incorporated by reference into this Registration Statement:
| (a) |
The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 30, 2023, as amended by the Form 10-K/A, filed with the SEC on April 28, 2023;
|
| (b) |
The Registrant’s Quarterly Report on Form 10-Q for the quarters ended March 31, 2023, June 30, 2023, and September 30, 2023, filed with the SEC on May 15, 2023, August 14, 2023, and November 14,
2023, respectively;
|
| (c) |
The Registrant’s Current Reports on Form 8-K, as applicable, filed with the SEC on January 9, 2023 (with respect to Item 8.01 only), February 9, 2023 (with respect to Item 8.01 only), February 15,
2023 (with respect to Item 8.01 only), March 16, 2023 (with respect to Items 1.01, 2.03, and 3.02 only), May 9, 2023 (with respect to Item 8.01 only), June 9, 2023, June 16, 2023, June 30, 2023, August 2, 2023 (with respect to Item 4.01
only), August 8, 2023 (with respect to Items 1.01, 2.03, and 3.02 only), August 30, 2023 (with respect to Items 1.01, 2.03, and 3.02 only), September 8, 2023, September 20, 2023 (with respect to Item 5.03 only), September 26, 2023, October 3,
2023 (with respect to Item 8.01 only), October 30, 2023 (with respect to Item 8.01 only), November 27, 2023, November 29, 2023 (with respect to Item 4.01 only)), December 11, 2023, December 13, 2023, December 20, 2023, December 29, 2023,
January 11, 2024 (with respect to Item 5.02 only), January 12, 2024, January 30, 2024 (with respect to Items 1.01, 3.02, and 8.01 only), and February 9, 2024; and
|
| (d) |
The description of the Registrant’s Common Stock set forth in the Registrant’s registration statement on Form 8-A/A filed with the SEC on October 31, 2022, and any amendment or report filed with the
SEC for the purposes of updating such description.
|
All other reports and other documents subsequently filed with the SEC by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of Exchange Act prior to the filing of a
post-effective amendment to this registration statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold (other than those furnished pursuant to Item 2.02 or Item 7.01 of Form 8-K or
other information deemed to have been “furnished” rather than “filed” in accordance with the SEC’s rules), shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such reports
and documents.
Any statement contained in a document incorporated or deemed to be incorporated by reference in this Registration Statement shall be deemed to be modified or superseded for purposes of
this Registration Statement to the extent that a statement contained in this Registration Statement, or in any other subsequently filed document that also is or is
deemed to be incorporated by reference in this Registration Statement, modifies or supersedes such prior statement. Any statement contained in this Registration Statement shall be deemed
to be modified or superseded to the extent that a statement contained in a subsequently filed document that is or is deemed to be incorporated by reference in this Registration Statement modifies or supersedes such prior statement. Any statement so
modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
Item 8. Exhibits.
A list of exhibits filed herewith is contained in the Exhibit Index that immediately precedes such exhibits and is incorporated herein by reference.
EXHIBIT INDEX
|
Exhibit
No. |
Document
|
|||
|
23.2*
|
Consent of Morgan, Lewis & Bockius LLP (included in Exhibit 5.1 hereto).
|
|
||
|
|
||||
|
107*
|
Filing Fee Table.
|
|||
* Filed herewith
+ Denotes compensatory plan
or arrangement
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Denver, State of Colorado on this 9th day of February, 2024.
|
SeaStar Medical Holding Corporation
|
||
|
By:
|
|
/s/ Eric Schlorff
|
|
Name:
|
|
Eric Schlorff
|
|
Title:
|
|
Chief Executive Officer
|
Each of the undersigned, whose signature appears below, hereby constitutes and appoints Eric Schlorff as his or her true and lawful attorney-in-fact and agent, with
full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any or all amendments to this registration statement and to file the same with all exhibits thereto and other
documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing necessary or appropriate to be done with respect to this registration statement
or any amendments hereto in the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or his or their substitute or
substitutes, may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the
capacities indicated below on February 9, 2024.
|
Name
|
Title
|
Date
|
|
/s/ Eric Schlorff
|
Chief Executive Officer and Director
(Principal Executive Officer)
|
February 9, 2024
|
|
Eric Schlorff
|
||
|
/s/ David Green
|
Chief Financial Officer
(Principal Financial and Accounting Officer)
|
February 9, 2024
|
|
David Green
|
||
|
/s/ Rick Barnett
|
Chairman of the Board of Directors
|
February 9, 2024
|
|
Rick Barnett
|
||
|
/s/ Kenneth Van Heel
|
Director
|
February 9, 2024
|
|
Kenneth Van Heel
|
||
|
/s/ Andres Lobo
|
Director
|
February 9, 2024
|
|
Andres Lobo
|
||
|
/s/ Allan Collins
|
Director
|
February 9, 2024
|
|
Allan Collins
|
||
|
/s/ Bruce Rodgers
|
Director
|
February 9, 2024
|
|
Bruce Rodgers
|
||
|
/s/ Richard Russell
|
Director
|
February 9, 2024
|
|
Richard Russell
|